A recent study reveals that individuals who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight far faster than those who end traditional lifestyle programs.
Findings released in a leading medical journal points out that while obese people often shed about a fifth of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using such drugs must be informed of the potential of rapid weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment mass within about a year and a half.
Weighing Approaches
The analysis, which examined 37 of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
Researchers emphasize that people who shed pounds through dieting typically have a slower weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Doctors believe the way of the jabs explains the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing the hormone levels far above than the body's typical production may cause the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement results in hunger is unsuppressed, making binge eating much more probable."
A Lifelong Condition?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals contend that, due to the significant potential of relapse, the therapy is often life-long.
This opinion is supported by pharmaceutical companies, who note that the results "highlight the chronic character of obesity," similar to managing diseases like high blood pressure.
Patient Testimonies
Users who have come off the medication describe a powerful return of cravings.
"It felt as if a switch activating and you become ravenous," described one woman.
The struggle is compounded if users have not developed lasting dietary or behavioural changes during therapy.
Significant Interest
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Finally, researchers emphasize that while the jabs are effective agents for weight loss, they are not a magic fix and long-term success relies on ongoing lifestyle support.
